Multiple Sclerosis (MS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Multiple Sclerosis (MS) Emerging Therapy and TPP Insights

Thelansis’s “Multiple Sclerosis (MS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Multiple Sclerosis (MS) Overview

Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating, and neurodegenerative disease of the central nervous system (CNS) fundamentally driven by autoreactive T-cell and B-cell infiltration across a compromised blood-brain barrier. This aberrant immune response orchestrates multifocal inflammatory cascades that precipitate profound myelin destruction, secondary axonal transection, and progressive gliosis, classically manifesting as sclerotic plaques within the periventricular, juxtacortical, infratentorial, and spinal cord compartments. Predominantly afflicting young adults, the disease classically presents with episodic, focal neurological deficits—most prevalently optic neuritis, internuclear ophthalmoplegia, transverse myelitis, and debilitating fatigue—governed by a hallmark dissemination in space and time. Definitive diagnosis strictly adheres to the McDonald criteria, relying heavily on magnetic resonance imaging (MRI) to detect characteristic lesions (such as Dawson’s fingers) alongside cerebrospinal fluid (CSF) analysis revealing pathognomonic, CNS-restricted oligoclonal bands. While acute exacerbations are rapidly managed with high-dose systemic corticosteroids, the modern longitudinal therapeutic paradigm has fundamentally shifted. The definitive standard of care now actively prioritizes early, aggressive intervention with high-efficacy disease-modifying therapies (DMTs)—most notably leveraging targeted anti-CD20 monoclonal antibodies (such as ocrelizumab), anti-alpha-4 integrin antagonists, or sphingosine-1-phosphate (S1P) receptor modulators—to robustly silence neuroinflammation, eradicate clinical relapses, and decisively prevent the irreversible accumulation of long-term neurological disability.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Multiple Sclerosis (MS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026